Serum MIF in Acute Kidney Injury

March 13, 2023 updated by: David M Baron, MD, PhD, Medical University of Vienna

Macrophage Migration Inhibitory Factor in the Serum of Critically Ill Patients as an Early Marker for Acute Kidney Injury

Acute kidney injury (AKI) is a common complication in critical care patients. Currently no parameters are available for early prognosis of AKI. Macrophage migration inhibitory factor (MIF) has been associated with AKI in clinical studies. The aim of this study is to evaluate the time course of MIF concentrations in patients with AKI.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Vienna, Austria, 1090
        • Medical University of Vienna

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Critical care patients

Description

Exclusion Criteria:

  • Age < 18 years and > 80 years
  • Patients with chronic dialysis
  • Patients with continuous hemodialysis, hemofiltration or hemodiafiltration within 4 weeks prior to the study
  • Patients with an expected length of ICU stay shorter than 3 days
  • Patients with a low probability of surviving the first 2 days after ICU admission
  • Pregnancy and nursing

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
AKI
Patients developing AKI during the ICU stay
Other: Blood draw for measurement of MIF
Observational study, no intervention
No AKI
Matched controls not developing AKI during the ICU stay
Other: Blood draw for measurement of MIF
Observational study, no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Macrophage migration inhibitory factor
Time Frame: Up to 14 days
Up to 14 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Serum creatinine
Time Frame: Up to 14 days
Up to 14 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medical University of Vienna

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2015

Primary Completion (Actual)

November 1, 2019

Study Completion (Actual)

January 1, 2023

Study Registration Dates

First Submitted

January 28, 2015

First Submitted That Met QC Criteria

January 28, 2015

First Posted (Estimate)

February 2, 2015

Study Record Updates

Last Update Posted (Actual)

March 15, 2023

Last Update Submitted That Met QC Criteria

March 13, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1680/2014

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Kidney Injury

Clinical Trials on Blood draw for measurement of MIF

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe